Long Term Survival and Continued Complete Response of Vemurafenib in a Metastatic Melanoma Patient with BRAF V600K Mutation

Introduction. BRAF kinase inhibitors such as Vemurafenib have shown improvement in overall survival, progression-free survival, and response rates in patients with metastatic melanoma with BRAF V600K mutation. However, there were no cases of complete remission reported in patients with V600K mutatio...

Full description

Saved in:
Bibliographic Details
Published in:Case Rep Oncol Med
Main Authors: Sahadudheen, K., Islam, Md. Rafiqul, Iddawela, M.
Format: Artigo
Language:Inglês
Published: Hindawi Publishing Corporation 2016
Subjects:
Case Report
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4775779/
https://ncbi.nlm.nih.gov/pubmed/26989536
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2016/2672671
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items